

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold in the United States except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. The Company does not intend to make any public offering of securities in the United States.*



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING
OF
WUXI XDC CAYMAN INC. ON THE MAIN BOARD OF
THE STOCK EXCHANGE OF HONG KONG LIMITED**

**LISTING OF WUXI XDC CAYMAN INC.
AND COMMENCEMENT OF DEALINGS**

References are made to the announcements of the Company dated July 9, 2023, October 20, 2023, October 29, 2023, November 6, 2023, November 7, 2023 and November 16, 2023 (the “**Announcements**”) in relation to the Proposed Spin-off and separate listing of the SpinCo, a subsidiary of the Company, on the Main Board of the Stock Exchange. Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

LISTING OF WUXI XDC CAYMAN INC. AND COMMENCEMENT OF DEALINGS

The Stock Exchange has granted approval for the listing of, and permission to deal in, the SpinCo Shares on the Main Board of the Stock Exchange.

Following the completion of the Global Offering, (i) listing of the SpinCo on the Main Board of the Stock Exchange took place on November 17, 2023; and (ii) dealings in the SpinCo Shares on the Main Board of the Stock Exchange commenced at 9:00 a.m. on November 17, 2023. The SpinCo Shares are traded in board lots of 500 each and the stock code is 2268.

Immediately upon completion of the Global Offering (including the Preferential Offering), the Company controls in aggregate approximately 50.91% of the total number of issued shares of the SpinCo (assuming the Over-allotment Option is not exercised and without taking into account any exercise of the share options granted under the pre-IPO share option schemes of the SpinCo) and the SpinCo remains a subsidiary of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, November 17, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*